Hengrui and Braveheart report 52-week data on HRS/BHB-1893 in obstructive HCM

On November 6, 2026, Hengrui Pharma and Braveheart Bio presented findings at the American Heart Association Scientific Sessions 2026 from a 52-week open-label extension of the Phase 2 study of the investigational cardiac myosin inhibitor HRS/BHB-1893 in patients with obstructive hypertrophic cardiomyopathy.¹ After a 12-week core period and washout, all 42 enrolled patients resumed treatment with the drug for an additional 52 weeks in the extension phase.¹

By the 52-week mark, mean peak oxygen uptake rose by 2.7 mL/kg/min from the extension baseline, and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score rose by a mean of 17.3 points over the same period.¹ On the obstruction measure, 79% of patients (33 of 42) reached a Valsalva LVOT gradient below 30 mmHg at Week 52, and 90% reached that threshold at least once during treatment.¹ Most patients, 57%, finished the study on the 40 mg twice-daily starting dose.¹

On safety, the companies said no on-treatment severe or serious adverse events occurred during the 52-week extension, and all treatment-emergent adverse events were mild or moderate, with none leading to permanent discontinuation.¹ Two patients had transient drops in left ventricular ejection fraction below 50% and both resumed treatment at a lower dose.¹

In a separate presentation, Braveheart reported new preclinical mechanistic data and additional analyses from the completed Phase 2 study in non-obstructive HCM, suggesting the drug improves diastolic function while preserving systolic function.¹ The companies also said Braveheart would hold an investor event to discuss a planned fixed-dose Phase 2b study in obstructive HCM called TRUEHEART-HCM.¹ Braveheart holds an exclusive worldwide license from Hengrui Pharma to develop, manufacture and commercialize HRS-1893 outside mainland China, Hong Kong, Macao and Taiwan.¹